Dr. Kumar on Updated Data from the MAIA Trial in Newly Diagnosed Multiple Myeloma

Shaji Kumar, MD, consultant, professor of medicine, the Division of Hematology, Department of Internal Medicine, Mayo Clinic, discusses the updated data from the phase 3 MAIA trial (NCT02252172) in newly diagnosed multiple myeloma.

The study compared the efficacy of daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone vs lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Data presented at the 2022 ASH Annual Meeting at a median follow-up of 64.5 months follow-up showed that there continues to be a significant improvement in progression-free survival (PFS) for the daratumumab arm compared with the control arm, Kumar explains. Patients treated with daratumumab plus lenalidomide and dexamethasone experienced a median PFS of 61.9 months, compared with 34.4 months for those given lenalidomide and dexamethasone alone.

Additionally, at a median follow-up of 73.6 months, a 35% reduction in the risk of death was observed for daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone. The median overall survival (OS) was not yet reached in daratumumab plus lenalidomide and dexamethasone arm, compared with 64.1 months for the lenalidomide plus dexamethasone arm. The 60-month OS rates were 66.7% in the experimental arm and 53.7% in the control arm.